drugset / Trial / NCT02411526
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multiple dose, PK and safety study in patients with chronic, stable schizophrenia or schizoaffective disorder.
Timeline
- Start
- 2015-02
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | 60 mg | Subcutaneous |
| Comparator | Risperidone | Other / unclassified | 90 mg | Subcutaneous |
| Comparator | Risperidone | Other / unclassified | 120 mg | Subcutaneous |
| Comparator | Risperidone | Other / unclassified | — | Intramuscular |
| Comparator | Risperidone | Other / unclassified | 2 mg | Oral |